Tetra Bio-Pharma (TSX.V: TBP) (OTCQB: TBPMF), a biopharmaceutical leader in cannabinoid-based drug discovery and development, is adding international expert Dr. Louis-Philippe de Lorimier, a board certified veterinary oncologist, to its clinical advisory board for the veterinary market. In a news release, Dr. Guy Chamberland, chief scientific officer of Tetra Bio-Pharma, said, “We are leveraging our current R&D work in humans to accelerate the development of the first cannabinoid-based drug for pets in the cancer-associated supportive therapy market, including pain. This market is underserved and patients and their owner are waiting for alternatives that are safer, more tolerable and more efficacious.”
Cancer is the leading cause of death in pets, affecting 50% of dogs above age eight and 40% of cats above 10 years of age. Tetra is developing cannabis-based products for the treatment of acute and chronic conditions that affect domestic animals, including cats, dogs and horses.
To view the full press release, visit http://cnw.fm/Iyd4e
About Tetra Bio-Pharma
Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements. Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. More information is available about the company at www.TetraBioPharma.com
More from CannabisNewsBreaks
About HempWire
HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
Turning Point Brands (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, recently…
WEED Inc. (OTCQB: BUDZ), a global cannabis and hemp bioresearch company based in the U.S.,…
Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate…
Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced its plans to host a Spaces call…
CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70…
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that…